PNPLA3 and hepatocellular carcinoma: Collectively, the PNPLA3 I148M variant represents not only a major genetic driver of MASLD and its complications but also a potential biomarker for fibrosis and HCC risk, as well as a promising target for precision therapeutics (111, 112).